Table 2 Proportion of patients with reduction in tumor size >0%, >10% and >30%, for patients with vs without selected resistance/sensitivity biomarkers
From: Fool’s gold, lost treasures, and the randomized clinical trial
Drug | Tumor type | Biomarker | % Biomarker-positive patients with tumor shrinkagea | % Biomarker-negative patients with tumor shrinkagea | ||||
|---|---|---|---|---|---|---|---|---|
Tumor shrank > 0% | Tumor shrank > 10% | Tumor shrank > 30% | Tumor shrank > 0% | Tumor shrank > 10% | Tumor shrank > 30% | |||
Panitumumab [52] | Colorectal | KRAS wild type | 57% | 50% | 25% | 4% | 1% | 0% |
Erlotinib [84] | NSCLC | EGFR mutant | 100% | 83% | 72% | 28% | 12% | 8% |
Erlotinib [85] | NSCLC | EGFR mutant | 100% | 83% | 50% | 31% | 17% | 3% |
Erlotinib [86] | NSCLC | EGFR mutant | 90% | 88% | 76% | |||
Erlotinib [87] | NSCLC | EGFR mutant | 100% | 80% | 70% | |||
Gefitinib [88] | NSCLC | EGFR mutant | 95% | 95% | 63% | 72% | 38% | 10% |
Gefitinib [89] | NSCLC | EGFR mutant | 91% | 82% | 55% | 67% | 33% | 0% |
Erlotinib or gefitinib [63] | NSCLC | EGFR mutant | 97% | 91% | 84% | 45% | 22% | 9% |
Crizotinib [90] | NSCLC | EML4/ALK fusion | 94% | 88% | 69% | |||
Vemurafenib [8] | Melanoma | BRAF V600E | 96% | 93% | 76% | |||